Tempest Therapeutics
TPST
28 hedge funds and large institutions have $7.29M invested in Tempest Therapeutics in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 7 closing their positions.
74% more call options, than puts
Call options by funds: $740K | Put options by funds: $425K
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
0.25% less ownership
Funds ownership: 0.9% → 0.65% (-0.25%)
10% less funds holding
Funds holding: 31 → 28 (-3)
26% less capital invested
Capital invested by funds: $9.88M → $7.29M (-$2.59M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$81.7K |
| 2 |
State Street
Boston,
Massachusetts
|
+$70K |
| 3 |
HF
HRT Financial
New York
|
+$50.7K |
| 4 |
VF
Virtu Financial
New York
|
+$45.4K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$41.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$617K |
| 2 |
Two Sigma Investments
New York
|
-$441K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$316K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$156K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$115K |
TPST Hedge Fund Activity: Q1 2024 in Review
28 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2024, worth a combined $7.29M — down 26% from $9.88M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TPST and 4 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 9 added.
The largest buyer was Jane Street, opening a new position worth an estimated $81.7K. The largest seller was EAM Investors, exiting entirely with an estimated $617K sold.
- 28 institutional investors held Tempest Therapeutics (TPST) as of Q1 2024, down from 31 in Q4 2023.
- Funds reported $7.29M of Tempest Therapeutics stock for Q1 2024, down 26% quarter-over-quarter.
- 4 funds opened new Tempest Therapeutics positions in Q1 2024 and 7 closed out, a net change of -3 holders.
- The largest Tempest Therapeutics buyer in Q1 2024 was Jane Street, an estimated $81.7K added.
- The largest Tempest Therapeutics seller in Q1 2024 was EAM Investors, an estimated $617K sold.
Based on aggregated 13F filings for Q1 2024.